title: The emergence of radioimmunoscintigraphy for prostate cancer.
abstract: The ability to label tissue-specific antibodies has long been of interest for improving detection and guidance for therapeutic applications. The most studied target for prostate cancer is the prostate-specific membrane antigen, which is upregulated in prostate cancer, hormone-refractive disease, and prostate cancer metastases. Investigations using radioimmunoscintigraphy with the radiolabeled 7E11 antibody capromab pendetide have significantly improved sensitivity for prostate cancer detection compared with standard cross-sectional imaging, based on tissue confirmation of pathologic results. Over the past 5 years, significantly greater image resolution from improved camera technology and the use of co-registration to fuse functional and anatomic (computerized tomography and magnetic resonance imaging) images have dramatically enhanced prostate cancer localization. Outcomes data from several sources have spurred a resurgence in interest in this imaging modality.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Keane
authors.forename: Inger L
authors.initials: IL
authors.lastname: Rosner
authors.forename: M Scott
authors.initials: MS
authors.lastname: Wingo
authors.forename: David G
authors.initials: DG
authors.lastname: McLeod